<DOC>
	<DOCNO>NCT00519064</DOCNO>
	<brief_summary>This phase III design confirm previous trial result evaluate safety , clinical tolerability immunogenicity 2006-2007 formulation Novartis Vaccines ' adjuvanted influenza vaccine subunit influenza vaccine adult underlie chronic disease .</brief_summary>
	<brief_title>Immunogenicity Safety Adjuvanted Inactivated Subunit Influenza Vaccine Those Non-adjuvanted Inactivated Subunit Influenza Vaccine , When Administered Adults Affected Chronic Diseases</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>18 60 year age adult volunteer , mentally competent , willing able give write informed consent prior study entry , suffer least one chronic disease : moderate severe hypertension , moderate severe congestive heart failure , chronic obstructive pulmonary disease ( COPD ) moderate severe asthma , moderate severe hepatic renal insufficiency , arteriosclerotic disease insulin dependent diabetes mellitus Hypersensitivity ovalbumin , chicken protein , chicken feather , influenza viral protein , neomycin polymyxin component vaccine ; History neurological symptom sign , anaphylactic shock follow administration vaccine ; Known suspect impairment/ alteration immune function ; Any condition might interfere evaluation study objective</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>influenza</keyword>
	<keyword>influenza vaccine</keyword>
	<keyword>adjuvanted influenza vaccine</keyword>
	<keyword>H5N1 influenza antigen</keyword>
</DOC>